Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Antibody Targeting Boosts Liposomal Drug Anticancer Activity

Abstract:
The first drug-loaded nanoparticle approved to treat cancer is in line for an upgrade. Researchers at Northeastern University have improved the tumor-killing activity of liposomal doxorubicin, known as Doxil™, by attaching a monoclonal antibody that recognizes a protein found on the surface of cancer cells. The resulting targeted liposome improves drug uptake by malignant cells and, more importantly, increases the potency of the original liposome by as much as eightfold. This work is reported in the European Journal of Pharmaceutical Sciences.

Antibody Targeting Boosts Liposomal Drug Anticancer Activity

Bethesda , MD | Posted on December 5th, 2007

To target liposomal doxorubicin, Vladimir Torchilin, Ph.D., and former graduate student Tamer Elbayoumi, Ph.D., used a monoclonal antibody discovered a decade ago by Torchilin and his colleagues. This antibody binds to a protein found in nucleosomes, a protein-DNA construct that organizes the chromosomes of all multicellular organisms, including humans. In healthy cells, nucleosomes are found only in the cell nucleus, but a broad variety of cancer cells contain a receptor on the cell membrane that recognizes nucleosomes. This particular monoclonal antibody, named mAb 2C5, recognizes and binds to that same receptor, while showing no propensity to bind to healthy cells. Each modified liposome contains approximately 70 to 80 surface-attached monoclonal antibodies.

Tests using a wide range of cultured tumor cells showed that mAb 2C5-targeted liposomal doxorubicin bound avidly to the cells. More importantly, uptake by those cells was rapid, far faster than with untargeted Doxil™ or Doxil™ modified with a control antibody that does not recognize tumor cells. Similarly, the targeted formulation was far more toxic toward all seven tumor cell lines tested, as it was in one preliminary in vivo study using a mouse xenograft model of human cancer. In addition, the investigators found that the targeted formulation, but not plain Doxil™, was also effective at killing a colon cancer cell line that is normally resistant to both Doxil™ and free doxorubicin.

This work is detailed in the paper "Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines." An abstract of this paper is available through PubMed.

####

About National Cancer Institute
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.

The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.

Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.

For more information, please click here

Contacts:
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda , MD 20892-2580

Copyright © National Cancer Institute

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

View abstract

Related News Press

Nanomedicine

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics September 25th, 2018

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics September 25th, 2018

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) September 25th, 2018

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

Discoveries

Searching for errors in the quantum world September 21st, 2018

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

UT engineers develop first method for controlling nanomotors: Breakthrough for nanotechnology as UT engineers develop first method for switching the mechanical motion of nanomotors September 21st, 2018

Silver nanoparticles are toxic for aquatic organisms: A research team at the UPV/EHU-University of the Basque Country has analysed how zebrafish are affected in the long term by exposure to silver particles September 19th, 2018

Announcements

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics September 25th, 2018

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics September 25th, 2018

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) September 25th, 2018

Viral RNA sensing: Optical detection of picomolar concentrations of RNA using switches in plasmonic chirality September 21st, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project